Viral Vaccines Market Intelligence

best-value

With this purchase you will be subscribed for a 12-month PRO membership to AI Powered Procurement Productivity Suite - Beroe LiVE.Ai

feature

 No Additional Benefits

Subscription Benefits:

  • PRO access to New Beroe LiVE*
  • Unlimited updates on the Report*
  • Supplier Watchlist for 3 suppliers*
  • Supplier Shortlisting Tool*

With this purchase you will be subscribed for a 12-month PRO membership to AI Powered Procurement Productivity Suite - Beroe LiVE.Ai

feature

*These features will be unlocked on the new Beroe LiVE when it launches (Q3, 2020)

Are you looking for answers on Viral Vaccines category?

Are you looking for answers on Viral Vaccines category?

  • What are the key trends in  Viral Vaccines category?
  • Am I paying the right price?
  • Am I working with the right supplier?
  • What are the major challenges and risks in  Viral Vaccines industry?
  • How is  Viral Vaccines industry performing?

Over 50,000+ users trust Beroe

Table of contents

  1. Viral Vaccines Executive Summary
  2. Executive Summary
  3. COVID-19 Update
  1. Viral Vaccines COVID-19 Update
  2. COVID-19 Update
  1. Viral Vaccines Market Analysis
  2. Global Market Size
  3. Regional Overview
  4. Porter’s Five Forces Analysis
  5. Market Trends
  6. Outsourcing Adoption Rate

 

  1. Viral Vaccines Industry Best Practices
  2. Best Practices-PricingModel
  3. Sourcing Alternatives

 

  1. Viral Vaccines Innovation Framework
  2. Innovations

 

  1. Viral Vaccines Innovation Framework
  2. Sustainability

Want a more detailed personalised report?

Viral Vaccines Global Market Outlook

There is an increasing awareness of immunization and a inspiration to formulate strong vaccine pipeline and the increasing focus of the key pharmaceutical players to develop innovative vaccines. These factors are driving the market with a CAGR of 8.7 percent and is expected to reach $81.27 billion by the end of 2027.

The market dynamics of research chemistry can be understood from the demand–supply perspective

  • From the demand side, pharmaceutical companies are facing pipeline issues and outsourcing additional activities. This trend has led to the emergence of outsourcing of production services, with emerging nations like India and China becoming favorable destinations
  • The viral vaccine production function is highly outsourced to leverage technical expertise and specific therapeutic area skill set at CROs

viral-vaccine

Regional Market Share 

It is easier to offshore more routine services, like Live-attenuated vaccine production and Subunit Vaccine production, to emerging regions, like India and China. However, services, like Toxiod Vaccines and Conjugated Vaccine Production that require strict regulatory guidelines, are mostly near shored to the developed markets

  • This is expected to change in the future with suppliers, like Wuxi AppTec, building capabilities in technologies, like computer-aided drug development and identify potential drug candidates in lesser time. Such factors will expedite the drug development process
  • Western markets are mainly involved in the niche service for chemistry function, whereas the transactional/routine functions under chemistry services are generally outsourced to the emerging market.

 

With this purchase you will be subscribed for a 12-month PRO membership to AI Powered Procurement Productivity Suite - Beroe LiVE.Ai

feature

Complimentary 12-month access to Beroe LiVE

Any more questions?

Get in touch with us quickly and easily.

x

COVID-19: Assess impact on your suppliers and ensure business continuity with Beroe’s WIRE
(World Instant Risk Exposure)